Alzinova AB (publ) presented data from studies with the Company's vaccine candidate ALZ-101 at the international Alzheimer conference AD/PDTM held in Gothenburg, March 28 - April 1 2023. The scientific poster shows that the vaccine candidate has a long-term effect and that antibodies are found in the brain in the expected amount. The results attracted great interest at the conference and several important contacts were established. Alzinova's Chief Scientific Officer Anders Sandberg presented a scientific poster at the conference summarizing preclinical data for the Company's vaccine candidate ALZ-101 (phase 1b study ongoing). The conclusion presented is that ALZ-101 stimulates the production of antibodies for a long time, and that these can reach the brain in relevant amounts. The vaccine thus seems to be effective also as a long-term treatment (chronic treatment) for Alzheimer's
disease. The presentation sparked great interest and resulted in meetings with investment firms, representatives from Big Pharma, important contacts with Key Opinion Leaders, and prominent researchers in the field. Potential disease-modifying therapies against the amyloid-beta peptide were discussed extensively during the conference, with many expecting them to become the standard of care for Alzheimer's disease. Another field that attracted great interest is biomarkers where great progress is being made, which for Alzinova's part could open up new methods for recruiting patients and, in the future, also enable the development of a preventive treatment where basically
healthy individuals are vaccinated before the disease has progressed.